These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Damy T; Pousset F; Caplain H; Hulot JS; Lechat P Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763 [TBL] [Abstract][Full Text] [Related]
25. Inhibitory Effect of Citalopram on the Pharmacokinetics of Carvedilol in Rats and in vitro Models. Abrudan MB; Muntean DM; Popa DS; Gheldiu AM; Neag MA; Vlase L Pharmacology; 2017; 100(5-6):301-307. PubMed ID: 28848215 [TBL] [Abstract][Full Text] [Related]
26. Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. Fukumoto K; Kobayashi T; Komamura K; Kamakura S; Kitakaze M; Ueno K Drug Metab Pharmacokinet; 2005 Dec; 20(6):423-7. PubMed ID: 16415527 [TBL] [Abstract][Full Text] [Related]
27. Unpredicted lack of effect of exercise on plasma concentrations of carvedilol. Stoschitzky K; Zweiker R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W J Cardiovasc Pharmacol; 2002 Jan; 39(1):58-60. PubMed ID: 11743228 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans. Baek IH; Yun MH; Yun HY; Kwon KI Arch Pharm Res; 2008 Jun; 31(6):814-21. PubMed ID: 18563366 [TBL] [Abstract][Full Text] [Related]
29. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo. Kindermann M; Maack C; Schaller S; Finkler N; Schmidt KI; Läer S; Wuttke H; Schäfers HJ; Böhm M Circulation; 2004 Jun; 109(25):3182-90. PubMed ID: 15184276 [TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. Othman AA; Tenero DM; Boyle DA; Eddington ND; Fossler MJ AAPS J; 2007 Jun; 9(2):E208-18. PubMed ID: 17614362 [TBL] [Abstract][Full Text] [Related]
31. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure. Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229 [TBL] [Abstract][Full Text] [Related]
32. Dose proportionality and pharmacokinetics of dronedarone following intravenous and oral administration to rat. Baek IH Xenobiotica; 2019 Jun; 49(6):734-739. PubMed ID: 29962267 [TBL] [Abstract][Full Text] [Related]
33. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Neugebauer G; Akpan W; Kaufmann B; Reiff K Eur J Clin Pharmacol; 1990; 38 Suppl 2():S108-11. PubMed ID: 1974498 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228 [TBL] [Abstract][Full Text] [Related]
35. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers. Honda M; Ogura Y; Toyoda W; Taguchi M; Nozawa T; Inoue H; Hashimoto Y Biol Pharm Bull; 2006 Apr; 29(4):772-8. PubMed ID: 16595916 [TBL] [Abstract][Full Text] [Related]
36. Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues. Stahl E; Mutschler E; Baumgartner U; Spahn-Langguth H Arch Pharm (Weinheim); 1993 Sep; 326(9):529-33. PubMed ID: 7902078 [TBL] [Abstract][Full Text] [Related]
37. Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study. Kim YH; Choi HY; Noh YH; Lee SH; Lim HS; Kim C; Bae KS Drug Des Devel Ther; 2015; 9():2911-8. PubMed ID: 26089641 [TBL] [Abstract][Full Text] [Related]
38. Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Wei L; Sun P; Nie S; Pan W Drug Dev Ind Pharm; 2005 Sep; 31(8):785-94. PubMed ID: 16221613 [TBL] [Abstract][Full Text] [Related]
39. Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies. Zarghi A; Foroutan SM; Shafaati A; Khoddam A J Pharm Biomed Anal; 2007 May; 44(1):250-3. PubMed ID: 17391893 [TBL] [Abstract][Full Text] [Related]